Piper Sandler Boosts Tempus AI (TEM) Stock Rating to Overweight with $76 Target

Key Highlights

Table of Contents

Piper Sandler shifted its stance on Tempus AI to Overweight from Neutral, boosting the price target from $56 to $76
Shares of TEM increased approximately 2.1-2.5% during Tuesday’s premarket session
Three key catalysts were identified: the acquisition of Personalis, favorable INTerpath-001 study results, and FDA clearance of the xT CDx test
Under the Personalis transaction terms, each share is valued at $16.25 in Tempus Class A stock, with an option for up to 50% cash payment
Canaccord Genuity maintained its Buy recommendation with an $80 target after the August 31 S-4 filing

Shares of Tempus AI (TEM) advanced between 2.1% and 2.5% during Tuesday’s premarket session following an upgrade by Piper Sandler analyst David Westenberg, who moved his rating from Neutral to Overweight while lifting his price objective to $76 from the prior $56 level.

Tempus AI, Inc., TEM

This upgrade represents a notable shift in Westenberg’s perspective on the company. His earlier Neutral stance reflected concerns that TEM’s market valuation was being propelled more by artificial intelligence enthusiasm than by the tangible results from its diagnostics operations and data platforms.

However, that assessment has evolved. Westenberg now points to three distinct growth catalysts that have emerged with greater clarity, strengthening his conviction in the company’s underlying business fundamentals.

The primary catalyst involves the upcoming Personalis acquisition. This transaction will provide Tempus with access to a tumor-informed minimal residual disease (MRD) platform, which Piper Sandler characterizes as a distinctive asset within the oncology diagnostics landscape.

The S-4 filing for this transaction was submitted on August 31. According to the terms disclosed, each Personalis share carries a $16.25 valuation, to be settled in Tempus Class A stock based on a ratio calculated from the Tempus share price. Additionally, Tempus retains the flexibility to substitute cash for as much as half of the stock consideration.

INTerpath-001 Study Results Enhance Strategic Positioning

The second catalyst stems from favorable results in the INTerpath-001 study. According to Westenberg, this outcome elevates the strategic importance of both Personalis and Tempus AI as the tumor sequencing provider for what may emerge as a novel therapeutic category.

These study results bolster Tempus’s competitive standing in the MRD sector during a period when the Personalis acquisition remains under review, establishing a more defined trajectory in the clinical sequencing marketplace.

FDA Approval Removes Critical Barrier for xT CDx

The third catalyst is the FDA’s approval of the tumor-only xT CDx test. According to Piper Sandler, this regulatory clearance eliminates a significant obstacle for Tempus as it works toward achieving unified ADLT pricing across its xT product portfolio.

The analyst noted that xF, a companion product, may pursue a comparable regulatory pathway during the latter half of 2027. Achieving unified ADLT pricing would materially influence Tempus’s revenue structure for these diagnostic products.

Canaccord Genuity also provided commentary after the August 31 S-4 filing, confirming its Buy rating on TEM while maintaining an $80 price target.

This positions Canaccord’s target modestly above Piper Sandler’s updated $76 projection, with both investment firms now carrying constructive views on the equity.

The August 31 S-4 filing stands as the latest official disclosure concerning the Personalis deal, making the transaction terms accessible for investor evaluation.

✨ Limited Time Offer